Ropidoxuridine

Phase 1Small molecule

SShuttle Pharmaceuticals, Inc.

Ropidoxuridine is one of 5 small molecule programs targeting Advanced Bile Duct Carcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Bile Duct CarcinomaActive, not recruiting

Whole Brain RadiationActive, not recruiting

Advanced Bile Duct CarcinomaPhase 1

Active, not recruiting

Whole Brain RadiationPhase 1

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Advanced Bile Duct Carcinoma

#DrugCompanyPhaseTrials

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 1

1 2

Gemzar

GGynecologic Oncology Group

Phase 1

1 3

Elimusertib

Bayer

Phase 1

1 4

Ropidoxuridine

SShuttle Pharmaceuticals, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Whole Brain Radiation

NCT02993146

Q1 2027

Phase 1Active, not recruiting

Advanced Bile Duct Carcinoma

NCT02381561

Clinical

Trials by Indication[1]

Whole Brain Radiation1 trial

Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT02993146·11 enrolled

Radiation Therapy1 trial

Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT04406857·1 enrolled

Glioblastoma1 trial

Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter

Terminated·SShuttle Pharmaceuticals, Inc.·Phase 2·NCT06359379·30 enrolled

Advanced Bile Duct Carcinoma1 trial

Phase I and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2'- Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Gastrointestinal Cancers

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT02381561·19 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Ropidoxuridine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ropidoxuridine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ropidoxuridine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shuttle Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SShuttle Pharmaceuticals, Inc.

Ropidoxuridine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Trials by Indication[1]

Whole Brain Radiation1 trial

Radiation Therapy1 trial

Glioblastoma1 trial

Advanced Bile Duct Carcinoma1 trial

References

Drug Info

Quick Facts

Related News